Trans-cranial Direct Current Stimulation on Alcohol Craving

Sponsor
Taipei City Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05854693
Collaborator
(none)
60
1
2
37.5
1.6

Study Details

Study Description

Brief Summary

The goal of thisclinical trial is to investigate the efficacy of trans cranial direct current stimulation (tDCS) for alcohol craving in individuals with alcohol dependence. The main question it aims to answer is whether 10 sessions of tDCS can reduce craving for alcohol.

Participants will be randomized into active group and sham group. Researchers will compare the severity of craving in these groups.

Condition or Disease Intervention/Treatment Phase
  • Device: transCranial direct current stimulation
  • Device: sham stimulation
N/A

Detailed Description

Craving is defined as strong desire for substance use, and is one of the core symptoms of alcohol dependence which is highly correlated with relapse. Transcranial direct current stimulation (tDCS) involves applying a small direct current (1-2mA) to the prefrontal cortex; its therapeutic effect for depression and cognition has been demonstrated by several randomized studies. Our preliminary study has shown that tDCS has the potential to reduce craving in alcohol-dependent patients without adverse events. Furthermore, our previous studies have shown that serum brain-derived neurotrophic factor (BDNF) level is elevated after alcohol withdrawal. The current study aims at examining the association between craving and serum BDNF level in alcohol-dependent patients receiving tDCS. The study recruits 40 patients with alcohol dependence. Patients will receive tDCS for 2 weeks during admission, and followed for 2 weeks after tDCS. We'll compare their improvements in craving scores every week, and investigate the correlation between craving and serum BDNF level. This study will bring innovations to the treatment of alcohol dependence based on our previous studies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Exploring the Effect of Trans-cranial Direct Current Stimulation on Craving and Serum BDNF of Patients With Alcohol Dependence
Actual Study Start Date :
Apr 17, 2023
Anticipated Primary Completion Date :
Jun 1, 2026
Anticipated Study Completion Date :
Jun 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active tDCS

The intervention consisted of 10 daily 20-min sessions of bilateral prefrontal tDCS (anodal-right/cathodal-left, 2mA; 1 × 1 Mini-CT)

Device: transCranial direct current stimulation
The intervention consisted of 20 daily 20-min sessions of bilateral prefrontal tDCS

Sham Comparator: Sham tDCS

The sham group consisted of 10 daily 20-min sessions of sham stimulation

Device: sham stimulation
The sham group consisted of 10 daily 20-min sessions of sham stimulation

Outcome Measures

Primary Outcome Measures

  1. Change in alcohol craving [Before intervention (week 0) and after intervention (week 2)]

    Measured by visual analog scale, from 0-10

Secondary Outcome Measures

  1. Change in brain-derived neurotrophic factor (BDNF) [Before intervention (week 0) and after intervention (week 2)]

    Serum level of BDNF

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Be between 20-65 years of age

  2. have sufficient cognitive function to understand the study and complete the informed consent process

  3. Be diagnosed with alcohol dependence as defined by DSM-IV through a structured interview (Mini-International Neuropsychiatric Interview, M.I.N.I.)

Exclusion Criteria:
  1. Intellectual disabilities

  2. bipolar disorder

  3. Psychosis (schizophrenia)

  4. Major physical illness (brain hemorrhage, brain tumor, myocardial infarction, epilepsy or history of seizures)

  5. intracorporeal electronic or metal implants (e.g., cardiac pacemaker)

  6. Pregnant or breastfeeding women

  7. Allergy to headgear and electrode materials

  8. Trauma or infection to the head

  9. Intracranial space occupied lesion (such as brain tumor, AVM, etc.) or patients who have undergone brain surgery, meningitis and encephalitis

  10. Patients who are expected to undergo brain and major surgery during the trial period

Contacts and Locations

Locations

Site City State Country Postal Code
1 Taipei City Hospital Taipei Taipei CITY Taiwan 105

Sponsors and Collaborators

  • Taipei City Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Taipei City Hospital
ClinicalTrials.gov Identifier:
NCT05854693
Other Study ID Numbers:
  • TCHIRB-10907010
First Posted:
May 11, 2023
Last Update Posted:
May 11, 2023
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Taipei City Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 11, 2023